In vivo detection of amyloid β deposition using 19F magnetic resonance imaging with a 19F-containing curcumin derivative in a mouse model of Alzheimer's disease

Neuroscience

Volumn 184, Issue , 2011, Pages 120-127

  Yanagisawa, D ^a   Amatsubo, T ^a   Morikawa, S ^a   Taguchi, H ^a   Urushitani, M ^a   Shirai, N ^b   Hirao, K ^b   Shiino, A ^a   Inubushi, T ^a   Tooyama, I ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b INDUSTRIAL RESEARCH CENTER OF SHIGA PREFECTURE   (Japan)

Author keywords

19F magnetic resonance imaging; Alzheimer's disease; Amyloid ; Amyloid imaging; Curcumin

Indexed keywords

1,7 BIS(4' HYDROXY 3' TRIFLUOROMETHOXYPHENYL) 4 METHOXYCARBONYLETHYL 1,6 HEPTADIENE 3,5 DIONE; AMYLOID BETA PROTEIN; CURCUMIN; FLUORINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG PENETRATION; DRUG STRUCTURE; HUMAN; HUMAN TISSUE; MOUSE; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN AGGREGATION; SENILE PLAQUE; TAUTOMER;

ALZHEIMER DISEASE; ANIMALS; BRAIN; CURCUMIN; DISEASE MODELS, ANIMAL; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, TRANSGENIC; PLAQUE, AMYLOID;

EID: 79955991824     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.03.071     Document Type: Article

References (29)

1. Amatsubo T., Morikawa S., Inubushi T., Urushitani M., Taguchi H., Shirai N., Hirao K., Kato M., Morino K., Kimura H., Nakano I., Yoshida C., Okada T., Sano M., Tooyama I. Trifluoromethoxy-benzylated ligands improve amyloid detection in the brain using 19F magnetic resonance imaging. Neurosci Res 2009, 63:76-81.
2. Amatsubo T., Yanagisawa D., Morikawa S., Tagchi H., Tooyama I. Amyloid imaging using high-field magnetic resonance. Magn Reson Med Sci 2010, 9:95-99.
3. Baum L., Lam C.W., Cheung S.K., Kwok T., Lui V., Tsoh J., Lam L., Leung V., Hui E., Ng C., Woo J., Chiu H.F., Goggins W.B., Zee B.C., Cheng K.F., Fong C.Y., Wong A., Mok H., Chow M.S., Ho P.C., Ip S.P., Ho C.S., Yu X.W., Lai C.Y., Chan M.H., Szeto S., Chan I.H., Mok V. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008, 28:110-113.
4. Burgos-Morón E., Calderón-Montaño J.M., Salvador J., Robles A., López-Lázaro M. The dark side of curcumin. Int J Cancer 2010, 126:1771-1775.
5. Cheng A.L., Hsu C.H., Lin J.K., Hsu M.M., Ho Y.F., Shen T.S., Ko J.Y., Lin J.T., Lin B.R., Ming-Shiang W., Yu H.S., Jee S.H., Chen G.S., Chen T.M., Chen C.A., Lai M.K., Pu Y.S., Pan M.H., Wang Y.J., Tsai C.C., Hsieh C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001, 21:2895-2900.
6. Goel A., Kunnumakkara A.B., Aggarwal B.B. Curcumin as "Curecumin": from kitchen to clinic. Biochem Pharmacol 2008, 75:787-809.
7. Hardy H., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
8. Higuchi M., Iwata N., Matsuba Y., Sato K., Sasamoto K., Saido C.T. 19F and 1H MRI detection of amyloid β plaques in vivo. Nat Neurosci 2005, 8:527-533.
9. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
10. Jack C.R., Knopman D.S., Jagust W.J., Shaw L.M., Aisen P.S., Weiner M.W., Petersen R.C., Trojanowski J.Q. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010, 9:119-128.
11. Klunk W.E., Engler H., Nordberg A., Wang Y., Blomqvist G., Holt D.P., BergstrLm M., Savitcheva I., Huang G.F., Estrada S., AusEn B., Debnath M.L., Barletta J., Price J.C., Sandell J., Lopresti B.J., Wall A., Koivisto P., Antoni G., Mathis C.A., LAngstrLm B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol 2004, 55:306-319.
12. Kudo Y., Okamura N., Furumoto S., Tashiro M., Furukawa K., Maruyama M., Itoh M., Iwata R., Yanai K., Arai H. 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer's disease patients. J Nucl Med 2007, 48:553-561.
13. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J Neurosci 2001, 21:8370-8377.
14. Mancuso C., Barone E. Curcumin in clinical practice: myth or reality?. Trends Pharmacol Sci 2009, 30:333-334.
15. Mandal P.K., Pettegrew J.W. Clinically relevant concentration determination of inhaled anesthetics (halothane, isoflurane, sevoflurane, and desflurane) by 19F NMR. Cell Biochem Biophys 2008, 52:31-35.
16. Mandal P.K., Bhavesh N.S., Chauhan V.S., Fodale V. NMR investigations of amyloid-β peptide interactions with propofol at clinically relevant concentrations with and without aqueous halothane solution. J Alzheimers Dis 2010, 21:1303-1309.
17. Mandal P.K., Simplaceanu V., Fodale V. Intravenous anesthetic diazepam does not induce amyloid-β peptide oligomerization but diazepam co-administered with halothane oligomerizes amyloid-beta peptide: an NMR study. J Alzheimers Dis 2010, 20:127-134.
18. Nordberg A. PET imaging of amyloid in Alzheimer's disease. Lancet Neurol 2004, 3:519-527.
19. Perrin R.J., Fagan A.M., Holtzman D.M. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009, 461:916-922.
20. Poduslo J.F., Curran G.L., Peterson J.A., McCormick D.J., Fauq A.H., Khan M.A., Wengenack T.M. Design and chemical synthesis of a magnetic resonance contrast agent with enhanced in vitro binding, high blood-brain barrier permeability, and in vivo targeting to Alzheimer's disease amyloid plaques. Biochemistry 2004, 43:6064-6075.
21. Poduslo J.F., Ramakrishnan M., Holasek S.S., Ramirez-Alvarado M., Kandimalla K.K., Gilles E.J., Curran G.L., Wengenack T.M. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J Neurochem 2007, 102:420-433.
22. Ramakrishnan M., Wengenack T.M., Kandimalla K.K., Curran G.L., Gilles E.J., Ramirez-Alvarado M., Lin J., Garwood M., Jack C.R., Poduslo J.F. Selective contrast enhancement of individual Alzheimer's disease amyloid plaques using a polyamine and Gd-DOTA conjugate antibody fragment against fibrillar A β 42 for magnetic resonance molecular imaging. Pharm Res 2008, 25:1861-1872.
23. Ran C., Xu X., Raymond S.B., Ferrara B.J., Neal K., Bacskai B.J., Medarova Z., Moore A. Design, synthesis, and testing of difluoroboron-derivatized curcumins as near-infrared probes for in vivo detection of amyloid-β deposits. J Am Chem Soc 2009, 131:15257-15261.
24. Ryu E.K., Choe Y.S., Lee K.H., Choi Y., Kim B.T. Curcumin and dehydrozingerone derivatives: synthesis, radiolabeling, and evaluation for β-amyloid plaque imaging. J Med Chem 2006, 49:6111-6119.
25. Sharma R.A., Euden S.A., Platton S.L., Cooke D.N., Shafayat A., Hewitt H.R., Marczylo T.H., Morgan B., Hemingway D., Plummer S.M., Pirmohamed M., Gescher A.J., Steward W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res 2004, 10:6847-6854.
26. Song Y., Morikawa S., Morita M., Inubushi T., Takada T., Torii R., Kitamura Y., Taniguchi T., Tooyama I. Comparison of MR images and histochemical localization of intra-arterially administered microglia surrounding β-amyloid deposits in the rat brain. Histol Histopathol 2006, 21:705-711.
27. Takata K., Kitamura Y., Yanagisawa D., Morikawa S., Morita M., Inubushi T., Tsuchiya D., Chishiro S., Saeki M., Taniguchi T., Shimohama S., Tooyama I. Microglial transplantation increases amyloid-β clearance in Alzheimer model rats. FEBS Lett 2007, 581:475-478.
28. Yanagisawa D., Shirai N., Amatsubo T., Taguchi H., Hirao K., Urushitani M., Morikawa S., Inubushi T., Kato M., Kato F., Morino K., Kimura H., Nakano I., Yoshida C., Okada T., Sano M., Wada Y., Wada K., Yamamoto A., Tooyama I. Relationship between the tautomeric structures of curcumin derivatives and their Aβ-binding activities in the context of therapies for Alzheimer's disease. Biomaterials 2010, 31:4179-4185.
29. Yang F., Lim G.P., Begum A.N., Ubeda O.J., Simmons M.R., Ambegaokar S.S., Chen P.P., Kayed R., Glabe C.G., Frautschy S.A., Cole G.M. Curcumin inhibits formation of amyloid β oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem 2005, 280:5892-5901.